ArticleCell research2016
Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.
Article in Cell research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Immunogenic Cell Death: Unlocking New Frontiers in Cancer Immunotherapy.Cancer innovation · 2026Review
- Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.Current treatment options in oncology · 2025Review
- CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival.Oncoimmunology · 2024Article
- Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.Human vaccines & immunotherapeutics · 2023Article
- Immunology and immunotherapy in gastric cancer.Clinical and experimental medicine · 2023Review
- Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.Cancer immunology, immunotherapy : CII · 2022Article
- From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.Journal of inflammation research · 2022Review
- Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation.Frontiers in immunology · 2021Review
- Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.Frontiers in immunology · 2021Review
- Review
- Immunotherapy for Gastric Cancer: Time for a Personalized Approach?International journal of molecular sciences · 2018Review
- Chimeric antigen receptor T cells: a novel therapy for solid tumors.Journal of hematology & oncology · 2017Review
- Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Frontiers in immunology · 2017Review
- New Chimeric Antigen Receptor Design for Solid Tumors.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.